Expanding Operations In China And India Will Open New Opportunities In Medical And Industrial Markets

Published
24 Sep 24
Updated
07 Aug 25
AnalystConsensusTarget's Fair Value
US$16.60
42.9% undervalued intrinsic discount
07 Aug
US$9.48
Loading
1Y
-12.1%
7D
33.3%

Author's Valuation

US$16.6

42.9% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on01 May 25
Fair value Decreased 22%

Shared on23 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on17 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on09 Apr 25
Fair value Increased 0.095%

AnalystConsensusTarget has increased discount rate from 9.3% to 10.9%.

Shared on02 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on26 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on19 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on11 Mar 25
Fair value Increased 27%

AnalystConsensusTarget has increased revenue growth from 2.4% to 3.1%, increased profit margin from 6.4% to 9.5%, decreased future PE multiple from 23.3x to 13.5x and increased discount rate from 8.1% to 9.1%.